title: [Clinical study of assessment of trisomy 21--precise risk evaluation in the first trimester of pregnancy].
abstract: BACKGROUND
  In the past a non invasive risk analysis for detecting specific chromosomal aberrations was only possible from week 15 of pregnancy. In this paper the practicability of first trimester screening is analysed.
  
  
  METHODS
  Blood samples were taken from 1000 pregnant women before a invasive prenatal diagnosis was performed. Total hCG, free beta-hCG and PAPP-A (pregnancy associated plasma protein A) was analysed. These data were combined with complete cytogenetic and ultrasonographic (CRL and nuchal translucency--NT) data.
  
  
  RESULTS
  In more than 90% of cases the NT was below 3 mm. Here the rate of normal karyotypes was 97.8%. In 61 cases a abnormal karyotype was found. Here in the most cases we found an elevated NT. Also in the most cases of trisomy 21 and 18 and in triploidies a characteristic ratio of hCG/free beta-hCG and PAPP-A was discovered. Combining NT and biochemical analysis, 85% of trisomies 21 could be discovered as a risk group.
  
  
  CONCLUSIONS
  This study demonstrates the possibilities of first trimester screening with a high detection rate for specific chromosomal aberrations.
  
  
  CONCLUSIONS
  First trimester screening should only be performed in specialised centers because determination of NT and risk analysis needs extensive experience.
authors.affiliation: Institut für Medizinische Genetik Nordrhein und Frauenklinik am Ev. Krankenhaus Oberhausen, Oberhausen. kontakt@eurogen.de
authors.forename: B
authors.initials: B
authors.lastname: Eiben
authors.forename: W
authors.initials: W
authors.lastname: Hammans
authors.forename: S
authors.initials: S
authors.lastname: Keuter
authors.forename: R
authors.initials: R
authors.lastname: Goebel
authors.forename: F
authors.initials: F
authors.lastname: Louwen
authors.forename: J
authors.initials: J
authors.lastname: Epplen
mesh_terms: D006063:Chorionic Gonadotropin / Q000097:blood*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood*; D002869:Chromosome Aberrations / Q000097:blood / Q000175:diagnosis / Q000235:genetics; D025063:Chromosome Disorders; D004314:Down Syndrome / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007621:Karyotyping; D008297:Male; D008403:Mass Screening; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism*; D011296:Prenatal Diagnosis; D018570:Risk Assessment; D016216:Ultrasonography, Prenatal
chemical_list: D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D011266:Pregnancy-Associated Plasma Protein-A